Posted On: 10/10/2014 8:34:42 AM
Post# of 30066
In my opinion, the Lympro section in the milestone list is incomplete now and little speculative. Here is the list as it is currently written:
01.) LymPro - 72 Patient LP-002 Clinical Study Enrollment (completed 9/12)
02.) LymPro - LP-002 clinical performance data results (completed 10/9)
03.) Lympro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - CLIA submission / CLIA launch (est. 4Q14)
- #3 is speculative and has not been set out by GC as a milestone. There has been an indication from Dave, through an email, that the ICON relationship could be expanded but nothing specific from GC about a JV. Might be misleading, but I do expect more from ICON relationship
- 68 patient extension to LP-002 study enrollment and full data release (est. 4Q14)
- RUO Market Launch (est. 4Q14)
01.) LymPro - 72 Patient LP-002 Clinical Study Enrollment (completed 9/12)
02.) LymPro - LP-002 clinical performance data results (completed 10/9)
03.) Lympro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - CLIA submission / CLIA launch (est. 4Q14)
- #3 is speculative and has not been set out by GC as a milestone. There has been an indication from Dave, through an email, that the ICON relationship could be expanded but nothing specific from GC about a JV. Might be misleading, but I do expect more from ICON relationship
- 68 patient extension to LP-002 study enrollment and full data release (est. 4Q14)
- RUO Market Launch (est. 4Q14)
(0)
(0)
